3. Class: T4 Synthetic Hormone Replacement IFU: Hypothyroidism

5. Class: T4 Synthetic Hormone Replacement IFU: Hypothyroidism

7. Class: Biguanide IFU: Type 2 Diabetes

9. Class: Thiazolidinedione IFU: Type 2 Diabetes

11. Class: Sulfonylurea IFU: Type 2 Diabetes

13. Class: Sulfonylurea 2 nd Generation IFU: Type 2 Diabetes

15. Class: Sulfonylurea 2 nd Generation IFU: Type 2 Diabetes

17. Class: Dipeptidyl peptidase- 4 inhibitor IFU: Type 2 Diabetes

19. Class: Long Acting Insulin IFU: Type 1 (Adults and Children) Type 2 (Adults)

21. Class: Short Acting Insulin IFU: Diabetes –SC injection, continuous subcutaneous insulin infusion (SCII), IV infusion

23. Class: Short Acting Insulin IFU: Diabetes –SC injection, continuous subcutaneous insulin infusion pump

25. Class: Bisphosphonate IFU: Treatment of postmenopausal osteoporosis and osteoporosis in men

27. Class: Bisphosphonate IFU: Prevention and treatment of post-menopausal osteoporosis

29. Class: Bisphosphonate IFU: Prevention and treatment of postmenopausal osteoporosis and glucocorticoid induced osteoporosis (men & women). Treatment to increase bone mass in men with osteoporosis. Treatment of Pagets disease of bone.

31. Class: Progestin & Estrogen IFU: Treatment of premenstrual disphoric disorder in women who choose an oral contraceptive as the method of birth control

33. Class: Progestin & Estrogen IFU: Moderate acne vulgaris in females at or older than 15 years of age, who have no known contraindications to oral contraceptive therapy, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.

35. Class: Estrogen IFU: Moderate to severe vasomotor symptoms of menopause. Vulvar and vaginal atrophy. Osteoporosis prevention (consider alternative treatments). Hypoestrogenism

37. Class: Selective estrogen receptor modulator (SERM) IFU: Prevention and treatment of osteoporosis in postmenopausal women

39. Class: Alpha 1A- Blocker IFU: BPH

41. Class: Type II 5a- reductase inhibitor IFU: BPH, to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery. To reduce risk of symptomatic progression of BPH, with doxazosin

43. Class: Type I and II 5a- reductase inhibitor (cGMP-specific) IFU: BPH, as monotherapy to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery, or in combination with tamsulosin

45. Class: Phosphodiesterase type 5 inhibitor (cGMP-specific) IFU: Erectile dysfunction

47. Class: Phosphodiesterase type 5 inhibitor (cGMP-specific) IFU: Erectile dysfunction

49. Class: Phosphodiesterase type 5 inhibitor (cGMP-specific) IFU: Erectile dysfunction

51. Class: Sympathomimetic IFU: Short-term monotherapy as adjunct. In management of exogenous obesity in patients with initial body mass at or above 30kg/m 2, or at or above 27kg/m 2 in presence of other risk factors